Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZNCF) FCF Margin (2016 - 2025)

Historic FCF Margin for Astrazeneca (AZNCF) over the last 15 years, with Q4 2025 value amounting to 27.59%.

  • Astrazeneca's FCF Margin fell 34700.0% to 27.59% in Q4 2025 from the same period last year, while for Dec 2025 it was 36.68%, marking a year-over-year increase of 36700.0%. This contributed to the annual value of 36.68% for FY2025, which is 36700.0% up from last year.
  • Per Astrazeneca's latest filing, its FCF Margin stood at 27.59% for Q4 2025, which was down 34700.0% from 45.49% recorded in Q3 2025.
  • Astrazeneca's FCF Margin's 5-year high stood at 1501.16% during Q1 2022, with a 5-year trough of 2.52% in Q4 2021.
  • Its 5-year average for FCF Margin is 122.02%, with a median of 33.28% in 2024.
  • As far as peak fluctuations go, Astrazeneca's FCF Margin surged by 14646500bps in 2022, and later crashed by -14656600bps in 2023.
  • Astrazeneca's FCF Margin (Quarter) stood at 2.52% in 2021, then skyrocketed by 809bps to 22.94% in 2022, then increased by 16bps to 26.72% in 2023, then increased by 16bps to 31.06% in 2024, then decreased by -11bps to 27.59% in 2025.
  • Its FCF Margin was 27.59% in Q4 2025, compared to 45.49% in Q3 2025 and 37.57% in Q2 2025.